StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck primaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q4 2023
39
Period ended Dec 31, 2023
Change on a year earlier
-27.8%
54 in Q4 2022
History
32 quarters
Since Q1 2016
Sources
7
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrimaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202339-27.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202341-34.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q2 2023Jun 30, 202353-17.2%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q1 2023Mar 31, 202380+37.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q4 2022Dec 31, 202254-16.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202263-10.0%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q2 2022Jun 30, 202264+6.7%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q1 2022Mar 31, 202258-10.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q4 2021Dec 31, 202165+4.8%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q3 2021Sep 30, 202170-5.4%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202160-6.2%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2021Mar 31, 202165+27.5%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q4 2020Dec 31, 202062-7.5%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2020Sep 30, 202074-3.9%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q2 2020Jun 30, 202064-9.9%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q1 2020Mar 31, 202051-13.6%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗

Breakdown

What makes up primaxin (imipenem and cilastatin, legacy) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Primaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M) ($M), quarterly Q1 2016–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_primaxin

See every metric in the Merck KPI table. Data updated Oct 26, 2026.